24 Participants Needed

RLS-0071 for COPD

Recruiting at 4 trial locations
CW
Overseen ByClaire Whitaker
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: ReAlta Life Sciences, Inc.
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of adults with moderate exacerbations of COPD.

Do I need to stop my current medications for this trial?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Are You a Good Fit for This Trial?

This trial is for adults with moderate COPD flare-ups, who've smoked at least the equivalent of a pack a day for 10 years. They must have been diagnosed with COPD previously, shown by specific lung function tests within the last year and be hospitalized due to their current flare-up.

Inclusion Criteria

You have smoked the equivalent of 10 packs of cigarettes per year for at least one year.
I have COPD, confirmed by a lung function test in the last year.
I have been diagnosed with a severe COPD flare-up without any other known cause.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive RLS-0071 or placebo three times a day for at least 3 days and up to 5 days

1 week

Follow-up

Participants are monitored for safety and effectiveness after treatment

60 days

What Are the Treatments Tested in This Trial?

Interventions

  • RLS-0071
Trial Overview The study is testing RLS-0071, a new peptide treatment for COPD exacerbations. Participants will either receive RLS-0071 or a placebo to assess the safety and how well it works in improving symptoms compared to not receiving the active drug.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: RLS-0071Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

RLS-0071 is already approved in United States for the following indications:

🇺🇸
Approved in United States as RLS-0071 for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

ReAlta Life Sciences, Inc.

Lead Sponsor

Trials
6
Recruited
220+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security